First case series of clozapine induced hypogammaglobulinaemia in England
Open Access
- 18 March 2021
- journal article
- Published by Peertechz Publications Private Limited in Annals of Psychiatry and Treatment
- Vol. 5 (1), 015-018
- https://doi.org/10.17352/apt.000025
Abstract
Evidence is emerging that clozapine can adversely affect immunoglobulin levels.Keywords
This publication has 10 references indexed in Scilit:
- Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)Journal of Clinical Pathology, 2020
- Activation of phosphoinositide 3-kinase delta by antipsychotic drugs: Preliminary resultsPharmacological Reports, 2018
- PI3K induces B-cell development and regulates B cell identityScientific Reports, 2018
- Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approachToxicology and Applied Pharmacology, 2017
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyJournal of Allergy and Clinical Immunology, 2016
- Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K PathwayPharmacology, 2016
- Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration projectAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2014
- Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signallingNature Reviews Immunology, 2013
- Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategyProceedings of the National Academy of Sciences of the United States of America, 2012
- Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatmentHealth Technology Assessment, 2006